Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis

Peng Li,Bin Wang,Gang Li,Lei Fu,Dongfeng Zhang,Ziyun Lin,Haihong Huang,Yu Lu
DOI: https://doi.org/10.1016/j.ejmech.2020.112538
IF: 7.088
2020-11-01
European Journal of Medicinal Chemistry
Abstract:<p><em>Mycobacterium tuberculosis</em> (<em>Mtb</em>) ATP synthase is an important target for treating drug-resistant infections and sterilizing the bacteria, spurring intensive efforts to develop new TB therapeutics based on this target. In this work, four novel series including furan-2(5<em>H</em>)-ketone (<strong>3</strong>, <strong>4</strong>), maleimide (<strong>5</strong>) and squaramide (<strong>6</strong>) derivatives were designed, respectively, through the strategy of scaffold morphing and hydrogen-bond introduction, using the selective <em>Mtb</em> ATP synthase inhibitor compound <strong>2</strong> as the lead compound. The result demonstrated that diamino substituted cyclobut-3-ene-1,2-dione compounds <strong>6ab</strong> and <strong>6ah</strong> displayed good to excellent <em>in vitro</em> anti-TB activities (MIC 0.452 ∼ 0.963 μg/mL) with low cytotoxicity (IC<sub>50</sub> &gt; 64 μg/mL). In addition, not only did compound <strong>6ab</strong> show effective activity against clinically isolated resistant strains, it also revealed good druggability profiles including improved metabolic stability, no hERG channel inhibition potential, and acceptable oral bioavailability. The preliminary result of docking study and <em>in vitro</em> anti-bedaquiline-resistant strain test compared to compound <strong>2</strong> suggested that <em>Mtb</em> ATP synthase is most likely the target of compound <strong>6ab</strong>. The structure-activity relationship laid a good foundation for the identification of novel squaramides as a potential treatment of drug-resistant tuberculosis.</p>
chemistry, medicinal
What problem does this paper attempt to address?